KDKeshava K. Datta

Keshava K. Datta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Keshava K. Datta has a total of 203 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    WEE1 opposes APC/CCDH1 activity to promote S phase entry

    by Luc-Alban Vuillemenot, Lucas G. Morales, Calin-Mihai Dragoi, Betheney R. Pennycook, Edward Harris, Liuyang C. Lin, William A. Weston, Jade-Ellen Brown, Emma Graham, Leelou Moulin, et al.

    WEE1 phosphorylates and inhibits the activity of cyclin-dependent kinases to prevent mitotic entry and establish a G2 DNA damage checkpoint 1–3 . Consequently, WEE1 inhibitors have been developed to be synthetically lethal in TP53- mutated tumours that become reliant on this WEE1-mediated checkpoint, and such inhibitors are undergoing clinical trials. However, WEE1 inhibitors also have efficacy in TP53- wild-type tumours, and many trials have been terminated owing to high levels of toxic side effects, suggesting that WEE1 has unknown functions. Here we show that WEE1 promotes cell cycle re-entry from quiescence (G0) by opposing the activity of the E3 ubiquitin ligase, anaphase-promoting complex–cyclosome bound to CDH1 (APC/C CDH1 ). WEE1 phosphorylates CDH1 ( FZR1 ) at key residues that mediate the interaction between CDH1 and APC/C. Cells with loss of function of WEE1 during G0/G1 have delayed S phase entry, impaired G1/S transition, abnormal S phase accumulation of cyclin-dependent kinase inhibitor p21 Cip1/Kip1 and a p21-dependent G2 arrest. Reduced expression of APC/C CDH1 or p21 renders cells more sensitive to acute WEE1 inhibition, and both pathways are downregulated in cells with acquired WEE1 inhibitor resistance. These results reveal a mechanism of cell cycle control that has implications for how WEE1 inhibitors should be used in the clinic.

  • Open Access

    Sex differences in cardiomyocyte proteomic responses to the cardiotoxic chemotherapy drug doxorubicin

    by Sanela Dozic, Michael G. Leeming, Keshava K Datta, Hitesh Kore, Erin J Howden, Benjamin L Parker, Lea M. D. Delbridge, Kate L Weeks

    Anthracyclines, including doxorubicin, are widely used chemotherapeutic agents, but dose-dependent cardiotoxicity limits their clinical utility and increases the risk of heart failure in cancer survivors. In paediatric patients, female sex is a significant risk factor for anthracycline-associated cardiotoxicity, yet pre-clinical studies rarely investigate sex differences in immature hearts. Here, we provide a proteomic dataset from primary cardiomyocytes, isolated from postnatal day 2 rat hearts and treated with a clinically relevant concentration of doxorubicin. Analysis of proteins present in all samples identified candidates previously shown to be regulated by doxorubicin in adult hearts, as well as candidates that may be specifically regulated in young hearts. This dataset provides a resource for generating hypotheses on molecular mechanisms contributing to sex differences in juvenile doxorubicin-induced cardiotoxicity.

  • Open Access

    Uncovering Shared and Tissue-Specific Molecular Adaptations to Intermittent Fasting in Liver, Brain, and Muscle

    by Yibo Fan, Senuri De Silva, Nishat I Tabassum, Xiangyuan Peng, Vernise Jt Lim, Xiangru Cheng, Keshava K Datta, Rohan Lowe, Terrance G Johns, Mark P Mattson, et al.

    Intermittent fasting (IF) has emerged as a powerful dietary intervention with profound metabolic benefits, yet the tissue-specific molecular mechanisms underlying these effects remain poorly understood. In this study, we employed comprehensive proteomics and transcriptomics analysis to investigate the systemic and organ-specific adaptations to IF in male C57BL/6 mice. Following a 16-hour daily fasting regimen (IF16) over four months, IF reduced blood glucose, HbA1c, and cholesterol levels while increasing ketone bodies, indicative of enhanced metabolic flexibility. Proteomic profiling of the liver, skeletal muscle, and cerebral cortex revealed tissue-specific responses, with the liver exhibiting the most pronounced changes, including upregulation of pathways involved in fatty acid oxidation, ketogenesis, and glycan degradation, and downregulation of steroid hormone and cholesterol metabolism. In muscle, IF enhanced pyruvate metabolism, fatty acid biosynthesis, and AMPK signaling, while suppressing oxidative phosphorylation and thermogenesis. The cerebral cortex displayed unique adaptations, with upregulation of autophagy, PPAR signaling, and metabolic pathways, and downregulation of TGF-beta and p53 signaling, suggesting a shift toward energy conservation and stress resilience. Notably, Serpin A1c emerged as the only protein commonly upregulated across all three tissues, highlighting its potential role in systemic adaptation to IF. Integrative transcriptomic and proteomic analyses revealed partial concordance between mRNA and protein expression, underscoring the complexity of post-transcriptional regulation. Shared biological signaling processes were identified across tissues, suggesting unifying mechanisms linking metabolic changes to cellular communication. Our findings reveal both conserved and tissue-specific responses by which IF may optimize energy utilization, enhance metabolic flexibility, and promote cellular resilience.

  • Open Access

    Effect of 3′,4′-Dihydroxyflavonol Eye Drops in a Rat Model of Dispase-Induced Proliferative Vitreoretinopathy

    by Elsa C. Chan, Cheng Zeng, Chi D. Luu, Carla J. Abbott, Nicholas T. Chan, Keshava K. Datta, Nicholas Williamson, Penelope J. Allen, Jennifer C. Fan Gaskin

    (1) Background: Proliferative vitreoretinopathy (PVR) is the most common cause of failure in retinal detachment surgery and often leads to blindness. Oxidative stress is known to contribute to scar formation; therefore, reducing oxidative stress may protect against PVR development. This study investigated the therapeutic effects of the antioxidant 3′,4′-dihydroxyflavonol (DiOHF) in two preclinical models of PVR. (2) Methods: A retinal pigment epithelial cell line (ARPE-19) was used to investigate the anti-fibrotic effects of DiOHF. PVR was induced in one eye of each animal using dispase. Animals then received either vehicle or DiOHF eye drops in both eyes for 28 days. Eyes were harvested for mass spectrometry to perform proteomic analysis or to quantify tissue accumulation of DiOHF. Proteomic analysis was also performed in ARPE to validate these findings. (3) Results: In DiOHF-treated eyes with induced PVR, proteomic profiles showed reduced fibrosis, inflammation, cell migration, and oxidative stress compared with vehicle-treated PVR eyes. The in vitro studies confirmed that DiOHF inhibited wound healing responses, cell contraction, proliferation, and the generation of reactive oxygen species in ARPE-19 cells. Proteomic analysis in ARPE-19 also showed a similar trend. (4) Conclusions: This study provides compelling evidence that DiOHF eye drops offer protective effects against PVR in preclinical models.

  • Open Access

    Evaluation of Nanoparticle-Based Plasma Enrichment on Individuals with Primary and Metastatic Pancreatic Cancer

    by Ching-Seng Ang, Nicholas A. Williamson, Chelsea Dumesny, Michael G. Leeming, Keshava Datta, Swati Varshney, Mehrdad Nikfarjam, Hong He

    Background and Methods: Using a nanoparticle-based enrichment (Proteonano) methodology on human plasma samples, we achieved a substantial increase in identified proteins from ~700 to >5000 proteins compared to neat plasma digest. In a small-scale pilot test, we applied this methodology to a small cohort of plasma samples from pancreatic cancer (PC) patients with different disease stages: (I) primary tumor and (II) metastases, and compared them with healthy controls. Most identified proteins are within the Human Plasma Proteome Project (HPPP) database, and more than 300 proteins are on the list of FDA-approved drug targets. Results: We observed a large and significant increase in ribosomal proteins in the plasma of patients with metastatic PC. ADH1C and ADH1B, both members of the alcohol dehydrogenase family, were particularly upregulated in patients with liver metastasis. Fifteen other predicted secreted and/or cell surface–associated proteins with known cancer associations are also significantly altered and would otherwise go undetected in neat, digested plasma. Conclusions: The significant increase in proteome depth allows a strong foundation for future large-scale experimental and comparative analysis. Lastly, similar conclusions could be reached from comparing different mass spectrometers (Orbitrap Astral and Orbitrap Ascend) and columns (depth and throughput) setups on the same dataset, although the depth approach on the newer Orbitrap Astral instrumentations can reveal additional insights in the plasma proteome.


  • Open Access

    Development of a novel therapy for systolic heart failure

    by Corey Pollock, Xilun Wang, Hussam Alsaraji, Joseph Menassa, George Mbogo, Dimuthu Angage, Benjamin Richards, Jason Glab, Keshava K Datta, Liana Theodoridis, et al.

    Heart failure presents a critical health challenge with a 5-year mortality rate of up to 50%. Conventional treatments often lead to bradycardia or hypotension due to their impact on patient hemodynamics. To address this issue, we utilized high-throughput drug screening combined with structure-activity relationship-based medicinal chemistry to develop a novel drug-like compound that effectively blocks the β-adrenergic receptor (β-AR) mediated apoptosis pathway. This compound demonstrated both safety and efficacy in pre-clinical mouse models without adversely affecting cardiac output. Through thermal proteome profiling mass spectrometry, we identified the compound’s target as Wdr3, a regulator of the Hippo signaling pathway. This target identification was further validated using CRISPR-based knockout experiments. Our findings provide a valuable framework for the development of hemodynamically neutral therapies aimed at treating systolic heart failure.

  • Open Access

    Uncovering Shared and Tissue-Specific Molecular Adaptations to Intermittent Fasting in Liver, Brain, and Muscle

    by Yibo Fan, Senuri De Silva, Nishat I. Tabassum, Xiangyuan Peng, Vernise Jt Lim, Xiangru Cheng, Keshava K. Datta, Rohan Lowe, Terrance G. Johns, Mark P. Mattson, et al.

    Intermittent fasting (IF) has emerged as a powerful dietary intervention with profound metabolic benefits, yet the tissue-specific molecular mechanisms underlying these effects remain poorly understood. In this study, we employed comprehensive proteomics and transcriptomics analysis to investigate the systemic and organ-specific adaptations to IF in male C57BL/6 mice. Following a 16-hour daily fasting regimen (IF16) over four months, IF reduced blood glucose, HbA1c, and cholesterol levels while increasing ketone bodies, indicative of enhanced metabolic flexibility. Proteomic profiling of the liver, skeletal muscle, and cerebral cortex revealed tissue-specific responses, with the liver exhibiting the most pronounced changes, including upregulation of pathways involved in fatty acid oxidation, ketogenesis, and glycan degradation, and downregulation of steroid hormone and cholesterol metabolism. In muscle, IF enhanced pyruvate metabolism, fatty acid biosynthesis, and AMPK signaling, while suppressing oxidative phosphorylation and thermogenesis. The cerebral cortex displayed unique adaptations, with upregulation of autophagy, PPAR signaling, and metabolic pathways, and downregulation of TGF-beta and p53 signaling, suggesting a shift toward energy conservation and stress resilience. Notably, Serpin A1c emerged as the only protein commonly upregulated across all three tissues, highlighting its potential role in systemic adaptation to IF. Integrative transcriptomic and proteomic analyses revealed partial concordance between mRNA and protein expression, underscoring the complexity of post-transcriptional regulation. Shared biological signaling processes were identified across tissues, suggesting unifying mechanisms linking metabolic changes to cellular communication. Our findings reveal both conserved and tissue-specific responses by which IF may optimize energy utilization, enhance metabolic flexibility, and promote cellular resilience.


  • Open Access

    Identification of Small Open Reading Frame-encoded Proteins in the Human Genome

    by Hitesh Kore, Satomi Okano, Keshava K Datta, Jackson Thorp, Parthiban Periasamy, Mayur Divate, Upekha Liyanage, Gunter Hartel, Shivashankar H Nagaraj, Harsha Gowda

    One of the main goals of the Human Genome Project is to identify all protein-coding genes. There are ∼ 20,500 protein-coding genes annotated in the human reference databases. However, in the last few years, proteogenomics studies have predicted thousands of novel protein-coding regions, including low-molecular-weight proteins encoded by small open reading frames (sORFs) in untranslated regions of messenger RNAs and non-coding RNAs. Most of these predictions are based on bioinformatics analyses and ribosome footprint data. The validity of some of these sORF-encoded proteins (SEPs) has been established through functional characterization. With the growing number of predicted novel proteins, a strategy to identify reliable candidates that warrant further studies is needed. In this study, we developed an integrated proteogenomics workflow to identify a reliable set of novel protein-coding regions in the human genome based on their recurrent observations across multiple samples. Publicly available ribosome profiling and global proteomic datasets were used to establish protein-coding evidence. We predicted protein translation from 4008 sORFs based on recurrent ribosome occupancy signals across samples. In addition, we identified 825 SEPs based on proteomic data. Some of the novel protein-coding regions identified were located in genome-wide association study (GWAS) loci associated with various traits and disease phenotypes. Peptides from SEPs are also presented by major histocompatibility complex class I (MHC-I), similar to canonical proteins. Novel protein-coding regions reported in this study expand the current catalog of protein-coding genes and warrant experimental studies to elucidate their cellular functions and potential roles in human diseases.


  • Open Access

    EPHA2-Ephrin-B1 cis -interaction supports self-renewal ability leading to recurrence of oral cancer

    by Reshma Raj R, Nandini Datta, Soumya Krishnan U, Geetha Shanmugam, Jiss Maria Louis, Ravichandran Damodaran Jeyaram, Keshava K Datta, Harsha Gowda, Meghna Sarkar, Madhumathy G Nair, et al.

    Eph-Ephrin pathway that drives a bidirectional signaling regulates a plethora of biological activities with its varied level of complexity. While the canonical trans -interaction of the ligand and receptor on neighboring cells initiates forward signaling that brings about biological activities, their cis -interaction on the same cell attenuates the forward signaling, modulating the biological effects. Yet, non-canonical cis -interactions with heterotypic surface proteins and kinases regulate certain biological effects. In cancer, the canonical signaling is believed to be tumor suppressive, while the ligand-independent non-canonical signaling drives tumor progression and poor prognosis. Self-renewal ability of cancer cells is a major underlying cause of recurrence and poor prognosis of cancer. Using SILAC-based proteomics, we identified Ephrin-B1 signaling as a crucial regulator of oral cancer self-renewal. Though Ephrin-B1 is known to regulate normal stem cells, its role in cancer remains underexplored. Our biochemical analyses show that Ephrin-B1 binds to a nonconventional receptor EPHA2, which is known to regulate cancer stem cells (CSCs), though the mechanism is less explored. Contrary to the belief that the cis -interaction of receptors and ligands is a means to block functional signaling, our immunoprecipitation, FRET facilitated photoswitching analysis, proximity ligation assay, and in vitro kinase assay provide evidence for the Ephrin-B1-EPHA2 cis -interaction leading to the phosphorylation of EphrinB1 at Y324/329 and Y317. Extreme limiting dilution assay in vitro and in vivo confirmed that this cis -interaction promotes CSC enrichment. Substantiating our in vitro results, mouse orthotopic models showed that Ephrin-B1/EPHA2 interaction regulates prognosis. The clinical relevance of the finding was validated using a TCGA data set and immunohistochemical analysis of tissue microarray using samples from oral cancer patients with recurrence in comparison to patients, who showed disease-free survival. Given that Ephrin-B interacts with EphB for normal stem cell homeostasis, this unconventional EPHA2/Ephrin-B1 cis -interaction, specifically manifested in CSC niches, might serve as an attractive target for therapy, warranting further validation.